Flebogamma DIF (Human Normal Immunoglobulin IVIg)
Intravenous immunoglobulin for immune deficiency and autoimmune conditions
Flebogamma DIF is a highly purified human normal immunoglobulin (IVIg) derived from pooled human plasma. It is administered intravenously to treat patients with primary and secondary immune deficiencies, as well as several autoimmune and inflammatory neurological conditions. This evidence-based guide covers indications, dosage, side effects, drug interactions, and precautions based on international clinical guidelines.
Quick Facts
Key Takeaways
- Flebogamma DIF is a plasma-derived immunoglobulin containing at least 97% IgG, used for both replacement therapy and immunomodulation in a wide range of conditions.
- It is approved for primary immunodeficiency (PID), secondary immunodeficiency (SID), primary immune thrombocytopenia (ITP), Guillain-Barré syndrome, Kawasaki disease, CIDP, and multifocal motor neuropathy (MMN).
- Administration is strictly intravenous, starting at a slow infusion rate (0.01–0.02 ml/kg/min) and may be increased up to 0.1 ml/kg/min if well tolerated.
- Serious but rare risks include anaphylaxis, thromboembolic events, renal impairment, and transfusion-related acute lung injury (TRALI) — patients with risk factors require close monitoring.
- Live vaccines (measles, mumps, rubella, varicella) should be delayed for at least 3 months after IVIg administration due to potential interference with vaccine efficacy.
What Is Flebogamma DIF and What Is It Used For?
Quick Answer: Flebogamma DIF is a highly purified intravenous immunoglobulin (IVIg) made from human plasma. It is used to replace missing antibodies in patients with immune deficiencies and to modulate the immune system in several autoimmune and inflammatory conditions, including ITP, Guillain-Barré syndrome, Kawasaki disease, CIDP, and MMN.
Flebogamma DIF contains human normal immunoglobulin, a highly purified protein extracted from the plasma of healthy blood donors. The product belongs to a group of medicines called immunoglobulins for intravenous use. These medicines are used to treat conditions in which the body's immune defence against infection does not work properly, or to modulate immune responses in autoimmune disorders.
The immunoglobulin in Flebogamma DIF consists of at least 97% immunoglobulin G (IgG), which provides a broad spectrum of antibodies against numerous infectious agents. The IgG subclass distribution is approximately 66.6% IgG1, 28.5% IgG2, 2.7% IgG3, and 2.2% IgG4, closely reflecting the distribution found in normal human serum. The product contains only trace amounts of IgA (less than 0.05 mg/ml).
Replacement Therapy (Antibody Deficiency)
Flebogamma DIF is used to treat adults, children, and adolescents (2–18 years) who do not have sufficient antibodies. There are two primary groups of patients who benefit from replacement therapy:
- Primary immunodeficiency (PID): Patients with congenital (inherited) antibody deficiency, such as common variable immunodeficiency (CVID), X-linked agammaglobulinaemia, and other genetic conditions that impair antibody production. These patients require lifelong immunoglobulin replacement to prevent recurrent, potentially life-threatening infections.
- Secondary immunodeficiency (SID): Patients who develop antibody deficiency due to other medical conditions or treatments (such as certain cancers, bone marrow transplantation, or immunosuppressive therapy) and experience severe or recurrent infections despite antimicrobial treatment. These patients must demonstrate either proven specific antibody failure (PSAF) or have serum IgG levels below 4 g/l.
Measles Prophylaxis
Flebogamma DIF can be used for measles prevention in susceptible adults, children, and adolescents (2–18 years) for whom active vaccination against measles is not indicated or not recommended. This includes both pre-exposure and post-exposure prophylaxis, particularly in immunocompromised patients who cannot receive live vaccines.
Immunomodulation (Autoimmune and Inflammatory Conditions)
Flebogamma DIF is also approved for treatment of several autoimmune and inflammatory conditions in adults, children, and adolescents (2–18 years). The immunomodulatory mechanism of IVIg is complex and involves multiple pathways, including Fc receptor blockade, anti-idiotypic antibodies, complement modulation, and cytokine regulation.
- Primary immune thrombocytopenia (ITP): A condition in which the number of platelets in the blood is severely reduced. Platelets play an important role in blood clotting, and patients with insufficient platelets are at high risk of bleeding and bruising. IVIg is particularly used in patients at high risk of bleeding or who require urgent surgery.
- Guillain-Barré syndrome (GBS): An acute autoimmune condition in which the immune system attacks peripheral nerves, causing progressive weakness, numbness, and potentially life-threatening respiratory failure. IVIg is one of two evidence-based first-line treatments for GBS (alongside plasma exchange).
- Kawasaki disease: A childhood vasculitis characterised by inflammation of blood vessels (particularly coronary arteries) throughout the body. IVIg is administered together with aspirin (acetylsalicylic acid) and has been shown to significantly reduce the risk of coronary artery aneurysms.
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A rare, progressive autoimmune condition that causes weakness, numbness, pain, and fatigue in the arms and legs due to damage to the myelin sheath of peripheral nerves. IVIg is a first-line treatment and can provide significant functional improvement.
- Multifocal motor neuropathy (MMN): A rare condition characterised by slowly progressive, asymmetric weakness in the limbs without sensory loss. IVIg is the only proven effective treatment for MMN and is considered the standard of care.
What Should You Know Before Using Flebogamma DIF?
Quick Answer: Flebogamma DIF must not be used in patients with known hypersensitivity to immunoglobulins, IgA deficiency with anti-IgA antibodies, or hereditary fructose intolerance. Patients with risk factors for blood clots, kidney disease, diabetes, or cardiovascular conditions require close medical monitoring during treatment.
Contraindications
You must not use Flebogamma DIF if any of the following apply:
- You are allergic (hypersensitive) to human normal immunoglobulin or any of the other ingredients in this medicine (including sorbitol).
- You have selective IgA deficiency and have developed antibodies against IgA. In such patients, treatment with IgA-containing products may lead to severe anaphylactic reactions.
- You have hereditary fructose intolerance (HFI), a rare inherited condition in which the enzyme that breaks down fructose is not produced. Infants and young children (under 2 years) must not receive this medicine, as they may not yet have been diagnosed with HFI, which can be fatal.
Patients with IgA deficiency who have developed anti-IgA antibodies are at risk of severe anaphylactic reactions. If you have been told you have low IgA levels, discuss this with your doctor before starting Flebogamma DIF. Flebogamma DIF contains trace amounts of IgA (less than 0.05 mg/ml).
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before using Flebogamma DIF. Certain side effects may occur more frequently in the following circumstances:
- At high infusion rates — the infusion should always be started slowly and increased gradually.
- If this is your first time receiving Flebogamma DIF, if you are switching from a different IVIg product, or if there has been a long interval since your last infusion. In these cases, you will be monitored carefully for up to one hour after infusion to detect any adverse effects.
Risk Factors for Thrombotic Events
Tell your doctor if you have any condition that increases your risk of blood clots (thrombotic events). Patients with the following risk factors require especially careful monitoring:
- Diabetes mellitus
- High blood pressure (hypertension)
- History of vascular disease or previous thrombosis
- Obesity or overweight
- Decreased blood volume (hypovolaemia)
- Conditions that increase blood viscosity
- Age over 65 years
- Prolonged immobilisation
Kidney Function
If you have kidney disease or are at risk of renal impairment, your doctor will take particular care. Acute kidney injury has been reported in association with IVIg therapy, particularly in patients with pre-existing renal insufficiency, diabetes, dehydration, obesity, concomitant nephrotoxic drugs, or age over 65 years. Your doctor may reduce the infusion rate or discontinue treatment if kidney problems develop.
Effects on Blood Tests
After receiving Flebogamma DIF, the results of certain blood tests (serological tests) may be temporarily affected. The passively transferred antibodies may lead to misleading positive results in tests such as Coombs test, hepatitis A, hepatitis B, and other pathogen-specific antibody assays. If you have a blood test after receiving Flebogamma DIF, inform the person taking the sample or your doctor that you are receiving this medicine.
When medicines are made from human blood or plasma, a number of measures are taken to prevent infections from being passed to patients. These include careful selection of blood and plasma donors, testing of individual donations and pools of plasma for signs of virus/infections, and inclusion of processing steps that can inactivate or remove viruses. Despite these measures, the possibility of transmitting infection cannot be entirely excluded. This also applies to any unknown or emerging viruses or other types of infections. The measures taken are considered effective for enveloped viruses such as HIV, hepatitis B, and hepatitis C, as well as for the non-enveloped hepatitis A virus and parvovirus B19.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. The safety of Flebogamma DIF in pregnancy has not been established in controlled clinical trials. However, immunoglobulin products have been used for many years in pregnant women and breastfeeding mothers, and no harmful effects on the course of pregnancy, the foetus, or the newborn have been observed. Immunoglobulins are secreted into breast milk and may contribute to protecting the newborn from certain pathogens.
Driving and Using Machines
Patients may experience reactions such as dizziness and nausea during treatment with Flebogamma DIF that can affect the ability to drive and use machines. If you experience any adverse effects during or after your infusion, wait until these have resolved before driving or operating machinery.
Important Information About Excipients
Sorbitol
Flebogamma DIF contains sorbitol as a stabiliser. Sorbitol is a source of fructose. If you or your child has hereditary fructose intolerance (HFI), you must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious adverse effects. Contact your doctor before receiving this medicine if you or your child has HFI, or if your child can no longer eat sweet food or drink without feeling sick, vomiting, or experiencing discomfort such as bloating, stomach cramps, or diarrhoea.
Sodium
This medicine contains less than 7.35 mg sodium (the main component of cooking/table salt) per 100 ml. This is equivalent to 0.37% of the recommended maximum daily dietary intake of sodium for an adult and is considered essentially sodium-free.
How Does Flebogamma DIF Interact with Other Drugs?
Quick Answer: Flebogamma DIF can reduce the effectiveness of live attenuated vaccines for up to 3 months (and up to 1 year for measles vaccines). Loop diuretics should be avoided during treatment. Always inform your doctor about all medications you are taking, including over-the-counter products and supplements.
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. It is important to inform your healthcare provider of all concurrent treatments, as interactions with certain medications can occur.
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Live attenuated vaccines (measles, mumps, rubella, varicella) | IVIg may reduce the efficacy of live vaccines by neutralising the vaccine virus through passively transferred antibodies | Wait at least 3 months after IVIg before administering these vaccines. For measles vaccine, wait up to 1 year. |
| Loop diuretics (furosemide, bumetanide) | May increase the risk of dehydration and renal complications during IVIg therapy | Avoid concurrent use during Flebogamma DIF treatment. Discuss alternatives with your doctor. |
Minor Interactions and Considerations
| Drug / Test | Effect | Notes |
|---|---|---|
| Serological blood tests | Passively transferred antibodies may cause false-positive results in certain serological assays | Inform laboratory personnel of recent IVIg therapy. Coombs test, hepatitis serology, and other antibody-based tests may be affected. |
| Blood glucose monitoring | Some IVIg products may contain maltose, which can interfere with blood glucose readings from certain glucometers | Flebogamma DIF contains sorbitol (not maltose) as stabiliser. However, confirm glucose monitoring method with your healthcare team. |
| Nephrotoxic medications | Concurrent use may increase the risk of renal adverse events | Your doctor may adjust the dose or infusion rate and ensure adequate hydration during therapy. |
If you need to receive a live vaccine, tell your doctor that you have recently received or are currently receiving immunoglobulin therapy. The required waiting period varies by vaccine type: 3 months for rubella, mumps, and varicella vaccines, and up to 1 year for measles vaccine. Your doctor will advise you on the appropriate timing.
What Is the Correct Dosage of Flebogamma DIF?
Quick Answer: The dosage of Flebogamma DIF depends on the indication and body weight. For replacement therapy in immunodeficiency, typical maintenance doses are 0.2–0.8 g/kg every 3–4 weeks. For immunomodulation (e.g., ITP, GBS), higher doses of 0.4–2 g/kg are used. The infusion always starts at a slow rate and is gradually increased.
Flebogamma DIF is given as an intravenous infusion (a drip into a vein). The dose and frequency of infusion depend on your medical condition, body weight, and clinical response. Your doctor will calculate the exact dose for you. In underweight or overweight patients, dose adjustments based on body weight may be necessary.
| Indication | Dose | Frequency |
|---|---|---|
| Primary Immunodeficiency (PID) | Starting: 0.4–0.8 g/kg Maintenance: 0.2–0.8 g/kg |
Every 3–4 weeks |
| Secondary Immunodeficiency (SID) | 0.2–0.4 g/kg | Every 3–4 weeks |
| Measles post-exposure prophylaxis | 0.4 g/kg | As soon as possible within 6 days of exposure; may be repeated once after 2 weeks |
| Measles pre-exposure prophylaxis (PID/SID) | 0.53 g/kg | Increase maintenance dose once to at least 0.53 g/kg if current dose is lower |
| Primary Immune Thrombocytopenia (ITP) | 0.8–1 g/kg or 0.4 g/kg/day |
Day 1, may repeat once within 3 days or for 2–5 days |
| Guillain-Barré Syndrome (GBS) | 0.4 g/kg/day | For 5 consecutive days |
| Kawasaki Disease | 2 g/kg | Single dose, together with aspirin |
| CIDP | Starting: 2 g/kg (over 2–5 days) Maintenance: 1 g/kg (over 1–2 days) |
Every 3 weeks |
| Multifocal Motor Neuropathy (MMN) | Starting: 2 g/kg (over 2–5 days) Maintenance: 1 g/kg or 2 g/kg |
Every 2–4 weeks (1 g/kg) or every 4–8 weeks (2 g/kg) |
Infusion Rate
Flebogamma DIF should always be infused intravenously at a controlled rate:
- Initial rate: 0.01–0.02 ml/kg/min for the first 30 minutes
- Maximum rate: If well tolerated, the rate may be gradually increased to a maximum of 0.1 ml/kg/min
Your healthcare provider will monitor your vital signs (temperature, blood pressure, heart rate, and breathing rate) during the infusion, especially if this is your first treatment or if you are switching from a different IVIg product.
Children (Over 2 Years of Age)
The dose for children is the same as for adults, as dosing is based on body weight and the specific indication being treated. Children’s vital signs should be monitored during infusion. Children under 2 years of age must not receive Flebogamma DIF due to the risk of undiagnosed hereditary fructose intolerance.
Missed Dose
If you miss a scheduled infusion of Flebogamma DIF, contact your doctor or healthcare provider immediately. Follow their instructions regarding rescheduling. Do not receive a double dose to make up for a missed treatment. Maintaining a regular infusion schedule is important, particularly for patients receiving replacement therapy for immunodeficiency.
Overdose
If you receive more Flebogamma DIF than prescribed, your body may accumulate excess fluid (fluid overload). This is particularly concerning in patients who are elderly or who have heart or kidney problems. Symptoms of fluid overload may include shortness of breath, swelling, and rapid weight gain. Tell your doctor immediately if you experience these symptoms. In the event of overdose, the infusion should be stopped and supportive care provided.
What Are the Side Effects of Flebogamma DIF?
Quick Answer: Common side effects include headache, fever, rapid heart rate, and low blood pressure. Serious but rare side effects include anaphylaxis, blood clots, kidney injury, and aseptic meningitis. Children tend to experience headache, fever, and low blood pressure more frequently than adults. Seek immediate medical attention for any signs of severe allergic reaction or breathing difficulty.
Like all medicines, Flebogamma DIF can cause side effects, although not everybody gets them. Most side effects are related to the infusion itself and can be managed by adjusting the infusion rate. Serious adverse reactions are rare but can be life-threatening and require immediate medical attention.
Contact your doctor or emergency services immediately if you experience any of the following during or after infusion: sudden drop in blood pressure, signs of anaphylaxis (rash, wheezing, difficulty breathing, rapid heartbeat), severe headache with neck stiffness (possible aseptic meningitis), chest pain or shortness of breath (possible thrombosis or TRALI), or significant decrease in urine output (possible kidney injury).
Side Effects by Frequency
Common
May affect up to 1 in 10 patients
- Headache
- Fever (elevated body temperature)
- Tachycardia (rapid heartbeat)
- Low blood pressure (hypotension)
Uncommon
May affect up to 1 in 100 patients
- Bronchitis
- Nasopharyngitis (common cold symptoms)
- Dizziness
- High blood pressure (hypertension)
- Wheezing
- Cough
- Abdominal pain (including upper abdominal pain)
- Diarrhoea
- Vomiting
- Nausea
- Urticaria (hives)
- Pruritus (itching)
- Skin rash
- Back pain
- Myalgia (muscle pain)
- Arthralgia (joint pain)
- Chills
- Pain at injection site
- Positive Coombs test
Rare
May affect up to 1 in 1,000 infusions
- Hypersensitivity reactions
- Abnormal behaviour
- Migraine
- Blood pressure fluctuations
- Flushing
- Cough and asthma
- Dyspnoea (difficulty breathing)
- Epistaxis (nosebleed)
- Nasal discomfort and throat pain
- Contact dermatitis and hyperhidrosis (excessive sweating)
- Muscle spasms, neck pain, and limb pain
- Urinary retention
- Asthenia (weakness) and chest pain
- Infusion site reactions (redness, leakage, inflammation, pain, oedema, swelling, itching)
- Peripheral oedema (swelling in arms and legs)
- Elevated alanine aminotransferase (liver enzyme)
Serious but Rare Adverse Events
In rare and isolated cases, the following serious adverse events have been reported with immunoglobulin products. These events require immediate medical attention:
- Anaphylactic shock: Sudden, severe allergic reaction with rapid drop in blood pressure, difficulty breathing, hives, and potentially loss of consciousness.
- Aseptic meningitis: Temporary inflammation of the membranes surrounding the brain, presenting with severe headache, light sensitivity, and neck stiffness. Usually resolves within days of stopping treatment.
- Haemolytic anaemia: Temporary reduction in red blood cells, which is usually reversible. May present with fatigue, pallor, and dark urine.
- Thromboembolic events: Blood clot formation that can lead to heart attack (chest pressure, rapid heartbeat), stroke (weakness, speech difficulty), pulmonary embolism (shortness of breath, chest pain), or deep vein thrombosis (pain and swelling in a limb).
- Acute kidney injury: Signs include lower back pain, fatigue, decreased urine output, and elevated creatinine levels. Risk is higher in patients with pre-existing kidney disease.
- Transfusion-related acute lung injury (TRALI): A serious pulmonary reaction causing oxygen deficiency, difficulty breathing, rapid breathing, cyanosis (bluish discolouration), fever, and low blood pressure.
Side Effects in Children and Adolescents
The rates of headache, fever, increased heart rate, and low blood pressure in children have been found to be higher than in adults. Vital signs (body temperature, blood pressure, heart rate, and respiratory rate) should be monitored during infusion in paediatric patients.
If you experience side effects, talk to your doctor, pharmacist, or nurse. This includes any side effects not listed here. By reporting side effects, you can help provide more information on the safety of this medicine. You can report suspected adverse reactions to your national medicines regulatory authority.
How Should You Store Flebogamma DIF?
Quick Answer: Store Flebogamma DIF at or below 30°C (86°F). Do not freeze. The solution should be clear to slightly opalescent. Do not use if cloudy or containing particles. Keep out of the reach and sight of children and check the expiry date before use.
Proper storage is essential to maintain the effectiveness and safety of Flebogamma DIF. Follow these guidelines:
- Temperature: Store at or below 30°C (86°F). Do not freeze the product. Frozen immunoglobulin should not be used.
- Light: Store in the original packaging to protect from light.
- Visual inspection: Before use, the solution should be clear to slightly opalescent and colourless or pale yellow. Do not use Flebogamma DIF if the solution is cloudy or contains particles or sediment.
- Temperature equilibration: Allow the product to reach room temperature (not exceeding 30°C) before use.
- Expiry date: Do not use after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
- Once opened: Use immediately after opening. Any unused solution should be discarded.
- Keep out of reach: Store out of the sight and reach of children.
- Disposal: Do not dispose of medicines via household waste or wastewater. Ask your pharmacist about proper disposal of unused medicines to help protect the environment.
It is strongly recommended that the product name and batch number (lot number on the label and carton) be recorded every time Flebogamma DIF is administered. This helps maintain a link between the patient and the specific batch of the product, which is important for safety monitoring of blood-derived products.
What Does Flebogamma DIF Contain?
Quick Answer: Each millilitre of Flebogamma DIF contains 50 mg of human normal immunoglobulin, of which at least 97% is IgG. The other ingredients are sorbitol and water for injections. The product is available in vials ranging from 0.5 g/10 ml to 20 g/400 ml. A 100 mg/ml formulation is also available.
Active Ingredient
The active substance is human normal immunoglobulin (IVIg). One millilitre of the 50 mg/ml formulation contains 50 mg of human normal immunoglobulin, of which at least 97% is immunoglobulin G (IgG).
Available Pack Sizes (50 mg/ml)
| Vial Size | IgG Content |
|---|---|
| 10 ml | 0.5 g |
| 50 ml | 2.5 g |
| 100 ml | 5 g |
| 200 ml | 10 g |
| 400 ml | 20 g |
IgG Subclass Distribution
The distribution of IgG subclasses in Flebogamma DIF closely mirrors the distribution found in normal human serum:
- IgG1: approximately 66.6%
- IgG2: approximately 28.5%
- IgG3: approximately 2.7%
- IgG4: approximately 2.2%
The product contains trace amounts of IgA (less than 0.05 mg/ml).
Other Ingredients (Excipients)
The other ingredients in Flebogamma DIF are:
- Sorbitol — used as a stabiliser. Important: patients with hereditary fructose intolerance must not receive this product.
- Water for injections
Appearance
Flebogamma DIF is a solution for infusion. The solution is clear to slightly opalescent and colourless or pale yellow. The product is supplied in glass vials. Each package contains 1 vial. Not all vial sizes may be available in all markets.
Frequently Asked Questions About Flebogamma DIF
Flebogamma DIF is manufactured by Instituto Grifols using a proprietary purification process. While all IVIg products contain human immunoglobulin G (IgG) derived from pooled plasma, they may differ in their stabilisers, IgA content, concentration, osmolality, and manufacturing processes. Flebogamma DIF uses sorbitol as a stabiliser and has very low IgA content (less than 0.05 mg/ml). Other IVIg products such as Gamunex-C (Grifols), Gammagard S/D (Takeda), Privigen (CSL Behring), and Octagam (Octapharma) may use different stabilisers such as glycine, glucose, or L-proline. The choice of IVIg product is typically made by your doctor based on your specific medical needs, tolerability, and product availability.
Yes, home infusion of Flebogamma DIF may be possible if you have received comprehensive training from hospital or healthcare personnel. You must learn how to prepare the infusion correctly to prevent bacterial contamination, and how to recognise and respond to adverse reactions. However, you must never infuse alone — a qualified healthcare professional experienced in product preparation, cannulation, administration, and adverse reaction monitoring must always be present during home infusions. Your doctor will determine whether home infusion is appropriate based on your medical history, treatment tolerance, and support system.
While formal controlled clinical trials in pregnant women have not been conducted, immunoglobulin products have been widely used in pregnant and breastfeeding women over many years. No harmful effects on the course of pregnancy, the foetus, or the newborn have been observed. IgG antibodies cross the placenta, particularly during the third trimester, and may provide some passive immunity to the newborn. However, as with all medications during pregnancy, the decision to use Flebogamma DIF should be made by your doctor after careful consideration of the benefits and risks.
The duration of a Flebogamma DIF infusion depends on the dose and the tolerated infusion rate. The infusion always starts slowly (0.01–0.02 ml/kg/min for the first 30 minutes) and is gradually increased to a maximum of 0.1 ml/kg/min if well tolerated. For a typical replacement therapy dose of 0.4 g/kg in a 70 kg patient (28 g), the infusion could take approximately 2–4 hours at the maximum tolerated rate, and longer if the rate needs to be kept low. Higher doses used for immunomodulation (e.g., 2 g/kg for Kawasaki disease) may require infusion over multiple days.
Flebogamma DIF is a blood-derived product, and despite extensive safety measures, the risk of transmitting infectious agents cannot be completely eliminated. However, the manufacturing process includes rigorous donor screening, testing of individual donations and plasma pools for viral markers, and multiple viral inactivation and removal steps. These measures are considered effective for enveloped viruses (HIV, hepatitis B, hepatitis C) and for the non-enveloped hepatitis A virus and parvovirus B19. Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections, likely because the antibodies present in the product provide protection against these pathogens.
All information is based on the European Medicines Agency (EMA) approved Summary of Product Characteristics, FDA prescribing information, WHO guidelines on the clinical use of immunoglobulin, peer-reviewed medical literature including Cochrane systematic reviews, and clinical guidelines from specialist societies such as EAACI and the European Federation of Neurological Societies (EFNS). All medical claims follow evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
References
- European Medicines Agency (EMA). Flebogamma DIF — Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed January 2026.
- Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–S553. doi:10.1016/j.jaci.2006.01.015
- Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46. doi:10.1016/j.jaci.2016.09.023
- Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063. doi:10.1002/14651858.CD002063.pub6
- Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893–908. doi:10.1111/j.1468-1331.2008.02246.x
- Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004;110(17):2747–2771. doi:10.1161/01.CIR.0000145143.19711.78
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
- World Health Organization. WHO Technical Report Series: Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. Geneva: WHO; 2023.
- Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021;28(11):3556–3583. doi:10.1111/ene.14959
- Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15(4):295–301. doi:10.1111/j.1529-8027.2010.00290.x
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians and clinical pharmacologists. Our editorial process follows strict evidence-based guidelines and every article undergoes multiple rounds of expert medical review.
All content is reviewed by board-certified physicians with expertise in immunology and clinical pharmacology, following international guidelines from WHO, EMA, FDA, and specialist medical societies.
We use the GRADE evidence framework to ensure all recommendations are based on the highest quality evidence available. Citations from peer-reviewed journals and official guidelines are required for all clinical claims.
For more information about our editorial standards and medical review process, visit our Editorial Standards page. To see all team members, visit our Medical Team page.